| Xianjin Yi, MD | |
|
301 Prospect Ave, Hospital Internists, Syracuse, NY 13203-1807 | |
| (315) 448-5704 | |
| (315) 423-6853 |
| Full Name | Xianjin Yi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 40 Years |
| Location | 301 Prospect Ave, Syracuse, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033312046 | NPI | - | NPPES |
| 03141646 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 254747 (New York) | Secondary |
| 207R00000X | Internal Medicine | 254747 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph's Hospital Health Center | Syracuse, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Josephs Medical Pc | 4688855844 | 291 |
News Archive
After the allergy drug Claritin became available without a prescription in 2002, insurance plans and consumers spent less on the prescription form of its main ingredient, loratadine, and all similar allergy drugs, according to a new report published in this month's The American Journal of Managed Care.
Western Dental, one of the nation's leaders in accessible, affordable oral health care, announced a first-of-its-kind research collaboration agreement with the University of California, San Francisco, a leading center of health sciences research, patient care, and education.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Cook Medical announced today that its Evolution Duodenal Controlled-Release Stent was recently granted 510(k) clearance by the Food & Drug Administration.
John Niederhuber, a surgeon whom President Bush on Tuesday appointed as National Cancer Institute director, on Wednesday said that he hopes to find new nontoxic cancer medications but added that the agency likely will have to eliminate some programs because of budgetary issues, the New York Times reports.
› Verified 5 days ago
| Entity Name | St Josephs Hospital Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508815333 PECOS PAC ID: 9234043324 Enrollment ID: O20031113000400 |
News Archive
After the allergy drug Claritin became available without a prescription in 2002, insurance plans and consumers spent less on the prescription form of its main ingredient, loratadine, and all similar allergy drugs, according to a new report published in this month's The American Journal of Managed Care.
Western Dental, one of the nation's leaders in accessible, affordable oral health care, announced a first-of-its-kind research collaboration agreement with the University of California, San Francisco, a leading center of health sciences research, patient care, and education.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Cook Medical announced today that its Evolution Duodenal Controlled-Release Stent was recently granted 510(k) clearance by the Food & Drug Administration.
John Niederhuber, a surgeon whom President Bush on Tuesday appointed as National Cancer Institute director, on Wednesday said that he hopes to find new nontoxic cancer medications but added that the agency likely will have to eliminate some programs because of budgetary issues, the New York Times reports.
› Verified 5 days ago
| Entity Name | St Joseph's Physician Health Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154376770 PECOS PAC ID: 9436041431 Enrollment ID: O20040325001159 |
News Archive
After the allergy drug Claritin became available without a prescription in 2002, insurance plans and consumers spent less on the prescription form of its main ingredient, loratadine, and all similar allergy drugs, according to a new report published in this month's The American Journal of Managed Care.
Western Dental, one of the nation's leaders in accessible, affordable oral health care, announced a first-of-its-kind research collaboration agreement with the University of California, San Francisco, a leading center of health sciences research, patient care, and education.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Cook Medical announced today that its Evolution Duodenal Controlled-Release Stent was recently granted 510(k) clearance by the Food & Drug Administration.
John Niederhuber, a surgeon whom President Bush on Tuesday appointed as National Cancer Institute director, on Wednesday said that he hopes to find new nontoxic cancer medications but added that the agency likely will have to eliminate some programs because of budgetary issues, the New York Times reports.
› Verified 5 days ago
| Entity Name | Apogee Medical Group, New York, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841520236 PECOS PAC ID: 4587793294 Enrollment ID: O20100518000664 |
News Archive
After the allergy drug Claritin became available without a prescription in 2002, insurance plans and consumers spent less on the prescription form of its main ingredient, loratadine, and all similar allergy drugs, according to a new report published in this month's The American Journal of Managed Care.
Western Dental, one of the nation's leaders in accessible, affordable oral health care, announced a first-of-its-kind research collaboration agreement with the University of California, San Francisco, a leading center of health sciences research, patient care, and education.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Cook Medical announced today that its Evolution Duodenal Controlled-Release Stent was recently granted 510(k) clearance by the Food & Drug Administration.
John Niederhuber, a surgeon whom President Bush on Tuesday appointed as National Cancer Institute director, on Wednesday said that he hopes to find new nontoxic cancer medications but added that the agency likely will have to eliminate some programs because of budgetary issues, the New York Times reports.
› Verified 5 days ago
| Entity Name | St Josephs Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942501747 PECOS PAC ID: 4688855844 Enrollment ID: O20110221000744 |
News Archive
After the allergy drug Claritin became available without a prescription in 2002, insurance plans and consumers spent less on the prescription form of its main ingredient, loratadine, and all similar allergy drugs, according to a new report published in this month's The American Journal of Managed Care.
Western Dental, one of the nation's leaders in accessible, affordable oral health care, announced a first-of-its-kind research collaboration agreement with the University of California, San Francisco, a leading center of health sciences research, patient care, and education.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Cook Medical announced today that its Evolution Duodenal Controlled-Release Stent was recently granted 510(k) clearance by the Food & Drug Administration.
John Niederhuber, a surgeon whom President Bush on Tuesday appointed as National Cancer Institute director, on Wednesday said that he hopes to find new nontoxic cancer medications but added that the agency likely will have to eliminate some programs because of budgetary issues, the New York Times reports.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Xianjin Yi, MD 301 Prospect Ave, Hospital Internists, Syracuse, NY 13203-1807 Ph: (315) 448-5704 | Xianjin Yi, MD 301 Prospect Ave, Hospital Internists, Syracuse, NY 13203-1807 Ph: (315) 448-5704 |
News Archive
After the allergy drug Claritin became available without a prescription in 2002, insurance plans and consumers spent less on the prescription form of its main ingredient, loratadine, and all similar allergy drugs, according to a new report published in this month's The American Journal of Managed Care.
Western Dental, one of the nation's leaders in accessible, affordable oral health care, announced a first-of-its-kind research collaboration agreement with the University of California, San Francisco, a leading center of health sciences research, patient care, and education.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Cook Medical announced today that its Evolution Duodenal Controlled-Release Stent was recently granted 510(k) clearance by the Food & Drug Administration.
John Niederhuber, a surgeon whom President Bush on Tuesday appointed as National Cancer Institute director, on Wednesday said that he hopes to find new nontoxic cancer medications but added that the agency likely will have to eliminate some programs because of budgetary issues, the New York Times reports.
› Verified 5 days ago
Courtney Myers, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 750 E Adams St Ste 311, Syracuse, NY 13210 Phone: 315-464-5815 | |
Joan Marie Mitchell, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-425-4828 Fax: 315-425-4827 | |
Gordana Obradovic, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1304 Buckley Rd, Suite 200, Syracuse, NY 13212 Phone: 315-478-3311 Fax: 315-476-5211 | |
Kristin A Ramella, NP Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 90 Presidential Plz Ste 5010, Syracuse, NY 13202 Phone: 315-464-9335 | |
Vinodhini M Subramanian, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-470-7111 | |
Robert R. Michiel, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 90 Presidential Plz, 5th Floor, Syracuse, NY 13202 Phone: 315-464-9335 Fax: 315-464-9338 | |
Michael P Gabris, MD FACC Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 E Genesee St, Suite 300, Syracuse, NY 13210 Phone: 315-471-1044 Fax: 315-474-4312 |